Print

Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy

https://www.facingourrisk.org/research-clinical-trials/study/221/adding-parp-inhibitor-to-enzalutamide-to-treat-men-with-metastatic-prostate-cancer-that-is-resistant-to-anti-androgen-therapy

Clinicaltrials.gov identifier:
NCT04455750 (https://clinicaltrials.gov/show/NCT04455750)

Treatment study for men with metastatic prostate cancer

Study Contact Information:

For additional information, please contact:
Arpit Rao, MD 713-798-4508 [email protected]

About this Study

This study is testing the effectiveness of adding a type of targeted therapy known as a PARP inhibitor to androgen-deprivation therapy for men with metastatic prostate cancer that has become resistant to standard androgen deprivation therapy. NOTE: This study is no longer enrolling people.

This Study is Open To:

NOTE: This study is no longer enrolling people.

This Study is Not Open To:

NOTE: This study is no longer enrolling people.

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.